A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NEW YORK, Feb. 10, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor...
NEW YORK, Feb. 07, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that the Company has appointed Anthony Dias as its new Vice President of...
Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of 66.7% and overall response rate of 60.5% After a median follow-up of...
NEW YORK, Jan. 25, 2022 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that David Hoffman has been appointed as General Counsel and Corporate...
NEW YORK, Jan. 07, 2022 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference: H.C. Wainwright...
On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall survival data continues to mature, a Hazard Ratio (HR) analysis of survival at...
Focus Trial Data and Future Development Plans to be Discussed by Management and KOLsNEW YORK, Nov. 30, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced...
NEW YORK, Nov. 09, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended...
NEW YORK, Nov. 08, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference: Canaccord...
NEW YORK, Nov. 05, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a comprehensive Investor Update event on Thursday, December 2nd,...